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Measures of Clinical Severity, Quality of Life, and Psychological
Distress in Patients with Psoriasis: A Cluster Analysis
Francesca Sampogna, Francesco Sera, Damiano Abeni, and the IDI Multipurpose Psoriasis Research on
Vital Experiences (IMPROVE) Investigators
The impact of psoriasis on patients’ quality of life may be quite destructive, and measures of disease status alone
seem to have questionable validity in describing the true burden of illness. Our aim was to study, in patients with
psoriasis, the relationship between classical measures of clinical status (i.e., PASI and SAPASI) and quality-of-
life indexes (i.e., Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index, Impact of Psoriasis
Questionnaire). In addition, two psychological distress indexes (i.e., Psoriasis Life Stress Inventory, 12-item
General Health Questionnaire) were assessed. Data were collected between February 2000 and July 2001 at the
inpatient wards of the Dermatological Institute IDI-IRCCS, Rome, Italy, in the framework of a large project on
clinical, epidemiologic, emotional, and quality-of-life aspects of psoriasis. A cluster analysis of all the above-
mentioned instruments was conducted on 786 eligible patients hospitalized with a diagnosis of psoriasis.
Correlations between instruments were also analyzed in subsets of patients based on the main variables of
interest. The instruments clustered in two distinct groups, one formed by clinical severity measurements and the
other grouping all the quality-of-life and psychological indexes. The correlations between instruments observed in
the subgroups determined by different sociodemographic and clinical variables showed the same pattern. In
conclusion, the dissimilarity between clinical severity assessment and patient-centered measures stresses the
need for a more comprehensive assessment of severity of psoriasis.
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Psoriasis has a substantial impact on patients’ lives.
Measures of disease status alone are generally considered
insufficient to describe the burden of illness (Wilson and
Cleary, 1995; Muldoon et al, 1998) and the physician
assessment of the extent of apparent disease in psoriasis
has been shown to be frequently a questionable indicator of
disease severity and impact (Marks et al, 1989; Finlay, 1997;
Fortune et al, 1997a, 2002). More patient-centered mea-
sures seem to be necessary to consider the patient’s
appraisal of the disease as it affects physically, psycholo-
gically, and socially his or her quality of life (McKenna and
Stern, 1996; Kirby et al, 2001). Until now, several instru-
ments have been created to evaluate the quality of life of
patients with psoriasis (Finlay and Coles, 1995; Gupta and
Gupta, 1995; McKenna and Stern, 1997) or in general with
dermatologic diseases (Finlay and Khan, 1994; Chren et al,
1997). These instruments, which consist of self-adminis-
tered questionnaires given to the patients, try to reflect the
way in which patients perceive and react to their health
status, assessing objective functioning, subjective well-
being, or both (Muldoon et al, 1998). Although they do not
include any direct information on clinical severity, it is
interesting to explore whether these measures are in some
way correlated to measures of disease status.
In this study, we quantified the clinical severity of
psoriasis using both physician- and patient-centered
indexes, and we measured the health-related quality of life,
using disease-specific as well as specialty-specific instru-
ments. In addition, we assessed psychiatric morbidity with
a validated questionnaire. We aimed at describing the
degree of correlation between these measures, and we
performed a cluster analysis to investigate how they group
together.
In this article we report results from data collected in a
large sample of patients of psoriasis hospitalized at the
Dermatological Institute IDI-IRCCS of Rome, included in
our ongoing IDI Multipurpose Psoriasis Research on Vital
Experiences (IMPROVE) study.
Results
In the survey days, there were 1237 hospitalizations for
psoriasis at IDI, regarding 1025 patients. Of these, 137 did
not satisfy the inclusion criteria. Of the 888 eligible
individuals, 102 did not agree to enter the study, so the
participation rate was 88.5% (n¼ 786).
The mean age of the patients was 45.5 y, and there were
465 men (59.2%) and 321 women. The majority of patients
had generalized plaque psoriasis (47.1%), 16.8% localized
Abbreviations: DLQI, Dermatology Life Quality Index; GHQ, 12-
item General Health Questionnaire; IPSO, Impact of Psoriasis
Questionnaire; PASI, Psoriasis Area and Severity Index; PDI,
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plaque, 12.8% guttate, 7.9% arthropatic, 7.3% palmoplan-
tar, and 2.0% pustular psoriasis. Erythrodermic psoriasis
and other rare forms (i.e., generalized, inverse, follicular, and
nail psoriasis) were grouped together because of the small
number of cases. The mean PASI score was 8.6 and the
mean age at onset was 33.6 years. As for global severity
as assessed by dermatologists, 24.7% of patients were
classified as severe or very severe, 29.0% as moderate, and
46.3% as mild.
Figure 1 shows the tree diagram for all the clinical
severity, quality-of-life, and psychological distress instru-
ments. The diagram was built on the basis of the similarity
between the instruments, measured by the correlation
coefficients shown in Table I. On the first steps, the
emotions and social functioning subscales of Skindex,
DLQI, PDI, IPSO, and PLSI merged in a group with high
correlation values, from 0.815 (Skindex emotions and
Skindex social functioning) to 0.600 (Skindex emotions
and PDI). The GHQ was then added to the previous group,
with correlation coefficients between GHQ and the grouped
instruments from 0.484 (PLSI) to 0.666 (IPSO). On the
following step, the symptoms subscale of Skindex merged
in the previous group (correlation coefficient from 0.433 to
0.598 with the other instruments). PASI and SAPASI merged
in a separate group. The correlation coefficients between
them and all the other instruments ranged from 0.049 for
the correlation between GHQ and PASI to 0.359 for the
correlation between PLSI and SAPASI. Therefore, at the end
of the clustering process, two main clusters could be
identified, one including only PASI and SAPASI and the
other encompassing all the quality of life and psychological
distress instruments. The replication of the cluster analysis
on five different random subsamples of the study population
gave the same results, thus supporting the validity of the
clusters obtained in the main analysis.
When considering the different levels of some socio-
demographic and clinical variables, a poor correlation was
invariably observed between clinical severity and quality-
of-life measurements. The majority of the correlation values
ranged from 0.1 to 0.3 for both psoriasis-specific and
dermatology-specific indexes. In general, the correlations
between quality-of-life measures and SAPASI were slightly
higher than those with PASI. Correlations between all
quality-of-life instruments and PASI and SAPASI were
slightly higher in women than in men (e.g., r¼ 0.171 and
r¼0.277 in men and women, respectively, for the correla-
tion between PASI and PDI) and slightly increased with
increasing severity. As to clinical type, in psoriatic arthritis
and in the guttate form correlations were higher than
in the other clinical types (e.g., respectively, r¼ 0.247 and
r¼0.257 between PASI and PDI).
As to psychological distress indexes, PASI and SAPASI
were more correlated with PLSI than with GHQ in all levels
of the considered variables. Moreover, the trend of the
correlation between clinical severity instruments and PLSI
was similar to the one observed with quality-of-life instru-
ments, whereas no particular trends were observed in the
correlations with GHQ.
No significant differences were observed in the other
sociodemographic variables, such as education and marital
status. Also in variables related to clinical characteristics
and symptoms, correlations between quality-of-life indexes
and clinical severity measurements were poor and did not
show significant differences in the different levels of the
variables.
Time of completion was o 24 h from admission in
approximately 55% to 60% of patients for the different
Figure 1
Tree diagram resulting from hierarchical cluster analysis of
measures of clinical severity, quality-of-life, and psychological
distress instruments.
Table I. Correlation matrix of clinical severity, quality-of-life, and psychological distress instruments
GHQ PLSI PDI DLQI IPSO
Skindex
SAPASISymptoms Emotions Social functioning
PASI 0.054 0.258 0.198 0.190 0.175 0.122 0.116 0.175 0.647
SAPASI 0.149 0.354 0.269 0.261 0.286 0.175 0.189 0.223
Skindex
Social functioning 0.615 0.663 0.710 0.723 0.781 0.598 0.815
Emotions 0.596 0.635 0.600 0.633 0.728 0.558
Symptoms 0.431 0.433 0.489 0.542 0.512
IPSO 0.666 0.738 0.798 0.758
DLQI 0.576 0.627 0.805
PDI 0.586 0.664
PLSI 0.484
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questionnaires andX 48 h only in 12% to 15% of cases. No
time-of-completion-related differences were observed. For
example, the correlation coefficients between PASI and
SAPASI in the four time categories of SAPASI completion
were 0.633, 0.650, 0.630, and 0.653. Correlation coeffi-
cients between PASI and the first quality of life completed
instrument (Skindex, social functioning) were 0.222, 0.166,
0.283, and 0.194, whereas between PASI and the last
completed quality-of-life instrument (PLSI) they were 0.328,
0.174, 0.301, and 0.234.
Discussion
In our study, cluster analysis showed two distinct groups of
instruments, one including only PASI and SAPASI, and the
other encompassing all quality of life and psychological
distress indexes. In addition, clinical severity measurements
showed almost invariably, for the different levels of the
various factors of interest, a poor correlation with different
indexes of quality of life and psychological distress in
patients with psoriasis. These results were strikingly similar
when considering the clinical severity evaluation performed
either by the physician (PASI) or by the patient (SAPASI).
A possible limitation of our observations is that they were
derived from patients hospitalized for psoriasis. Although it
is probable that our study population is selectively enriched
with more severe cases, it should be considered that
psoriasis hospitalization patterns in Italy are vastly different
from the United States and other countries. In fact, as it
can be seen from the description of the population under
Results, a large proportion of cases with mild to moderate
severity, as well as a wide range of clinical types, are
included in our study.
Previous studies investigating the relationship between
clinical variables and quality of life in psoriasis have also
found poor correlation (Fortune et al, 1997a, 2002; Touw
et al, 2001), with coefficients comparable to our results
(i.e., in the range of approximately 0.15–0.40). Such poor
correlations do not seem to depend, in our study, on the
time interval between PASI assessment and questionnaire
completion. In fact, SAPASI was given as the last instrument
and its correlation with PASI was excellent. In addition,
among the quality-of-life instruments, PLSI was the last to
be completed, but it showed the highest correlation with
PASI, whereas GHQ was completed as second but gave
the only non-statistically significant correlation with PASI.
Furthermore, the stratified analysis (see Results) showed
that correlation coefficients did not change with increasing
time intervals between PASI and quality-of-life assessment.
In contrast, the high correlation between quality-of-life
instruments does not seem to be due to test fatigue nor to a
possible ‘‘halo effect.’’ For instance, we have checked
correlations between similar items in different question-
naires (e.g., item 4 of Skindex-29, ‘‘My skin condition makes
it hard to work or do hobbies,’’ and item 7 of DLQI, ‘‘Has
your skin prevented you from working or studying?’’), and
we observed that correlation coefficients were similar in the
different combinations of time-of-completion categories.
Measures of health-related quality of life should consider
patients’ objective functioning or subjective well-being or
both (Muldoon et al, 1998). It is clear that whereas functional
assessment is expected to be close in some way to clinical
status, subjective well-being concerns the way in which
patients live with their disease and it does not necessarily
depend completely on severity. As has been pointed out
(Guyatt et al, 1993), quality of life is at least partly
independent of health status and ‘‘is a reflection of the
way that patients perceive and react to their health status
and to other nonmedical aspects of their lives’’ (Gill and
Feinstein, 1994). This would be particularly true if, as has
been suggested (Gill and Feinstein, 1994; Anonymous,
1995), only perceived well-being, not functional assess-
ment, were used to determine quality of life. The instru-
ments we used in our study included both objective
functioning and subjective well-being components, even
though in different proportions. In instruments intended to
assess the psychosocial impact of psoriasis, such as PLSI
and IPSO, the subjective component is predominant.
Nevertheless, the personal evaluation of problems in daily
activities, which is scrutinized through several questions in
PDI and DLQI, also has a strong subjective component in
addition to a connection with clinical severity of the disease.
On its side, GHQ considers only the subjective well-being,
because it is intended to assess psychological distress. The
predominance of the subjective component in our quality-
of-life instruments could explain the poor correlation
between them and clinical severity measurements. As a
matter of fact, the personal way of coping with psoriasis,
like many other dermatologic diseases, is not necessarily
correlated to the extent of the disease or to clinical
characteristics such as desquamation, induration, or
erythema, considered as main features of the disease by
PASI and SAPASI. Moreover, it has been demonstrated that
subjective indices of quality of life correlate reliably with
standard measures of psychiatric symptoms such as
depression or anxiety, suggesting in this sense that they
do measure subjective well-being, thus satisfying the
criterion of convergent validity (McHorney et al, 1993). It is
of some relevance to note that the correlation between the
symptoms scale of Skindex-29 and both PASI and SAPASI
is strikingly poor (r¼0.122 and r¼ 0.175, respectively).
Although this scale is close to the concept of clinical
severity, it includes symptoms such as itching, bleeding,
and burning, which are actually not taken into account in
disease severity measurements, such as PASI and SAPASI.
Moreover, the similarity of the results concerning PASI
and SAPASI is not surprising, because these measures have
been shown to be highly correlated (Sampogna et al, 2003).
As a matter of fact, even though compiled by the patient,
the SAPASI score is based on observable signs of disease
and does not consider symptoms nor implications on
patients’ emotional life and social functioning. It is interest-
ing to note how the SAPASI appears to constrain patients to
provide an objective assessment of their lesions, relatively
unpolluted by their subjective impression of the impact of
those lesions on their lives.
Psoriasis-specific quality-of-life instruments do not
correlate with PASI and SAPASI better than the dermatol-
ogy-specific ones, such as DLQI and Skindex. Indeed,
disease-specific instruments strongly correlate with derma-
tology-specific ones, with the exception of the symptoms
scale of the Skindex-29, thus suggesting that they collect
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very similar information on quality of life. This observation
shades some doubts, as recently noted though for different
reasons (de Korte et al, 2002), on the opportunity to
use psoriasis-specific quality-of-life instruments given that
they do not allow to make comparisons with other skin
conditions.
The dissimilarity between clinical severity assessment
and patient-centered measures stresses the need for recon-
ceptualization of psoriasis severity. It has been recently
proposed (Krueger et al, 2000) that a quality-of-life standard
would be better than a body surface area measurement for
delineating psoriasis severity. Our results indicate that both
approaches may be necessary for discriminative purposes
(i.e., to measure differences cross-sectionally between pati-
ents in different groups) and for evaluative purposes (i.e., to
measure differences longitudinally to study, for example, the
natural history of the disease or to evaluate a new drug for
approval). In fact, changes in clinical severity reflect the
biologic relevance of an intervention (e.g., a new treatment),
whereas quality of life measures quantify how those
changes impact on the daily life of the patients.
In the years of the third revolution in medical care
(McKenna and Stern, 1996), with the necessity of focusing
on the person rather than the disease, a more comprehen-
sive assessment of psoriasis seems to be necessary. The
road for future studies, intended to blend diverse measures
into a comprehensive one with solid quantitative features
and good psychometric properties, seems to be well
delineated.
Materials and Methods
Participants This study was carried out on patients with psoriasis
enrolled in a wider project on clinical, epidemiologic, emotional,
and quality-of-life aspects of psoriasis (IMPROVE study). Data
included in this report were collected between February 21, 2000,
and July 31, 2001, at the inpatient wards of the Istituto
Dermopatico dell’Immacolata (IDI-IRCCS), a large dermato-
logic hospital located in the city of Rome, Italy. Presently, at IDI-
IRCCS a wide range of clinical presentations of psoriasis are
hospitalized, including at times mild and moderate severity cases.
Such patients come especially from the more disadvantaged
central and southern regions for diagnostic procedures and
treatments (e.g., PUVA) that may not be available in their areas
of residence.
During the study period, patients hospitalized at IDI-IRCCS with
a diagnosis of psoriasis were contacted by our research staff. After
the diagnosis of psoriasis was confirmed by the senior staff of the
hospital, specifically trained dermatologists verified the inclusion
criteria and explained the purposes and methods of the study to
the patients. Inclusion criteria were 18 y of age or more, absence
of any severe mental or physical illness, at least 5 y of education,
ability to read Italian, and first hospitalization for psoriasis since the
date of the beginning of the study. All eligible patients who gave
their written informed consent were recruited in the study. Ethical
approval was granted by the Institutional Review Board and the




Psoriasis Area and Severity Index Clinical severity was assessed
by the physicians using the psoriasis area and severity index (PASI)
(Fredriksson and Pettersson, 1978; Marks et al, 1989; Ashcroft
et al, 1998). To complete the PASI, the dermatologists had to
estimate the proportion of involved area for each body district
(head, trunk, upper and lower extremities). The area of psoriatic
involvement for each of the four regions was then assigned a
numerical value of 0 to 6 corresponding to 0% to 100%
involvement: 0, no involvement; 1, o 10%; 2, 10% to o 30%; 3,
30% too 50%; 4, 50% too 70%; 5, 70% too 90%; and 6, 90%
to 100%. For each region, erythema, desquamation, and indura-
tion of the plaques were rated according to the classical 5-point
scale: 0, no involvement; 1, slight; 2, moderate; 3, marked; and 4,
very marked.
PASI scores were then calculated by investigators using
electronic spreadsheets to implement the formulas originally
proposed (Fredriksson and Pettersson, 1978). The PASI score
can vary from 0 to 72, with higher scores indicating more severe
conditions.
Self-administered PASI Patients determined clinical severity com-
pleting the self-administered PASI (SAPASI) (Feldman et al, 1996).
It is a structured, validated instrument, which we previously tested
in subgroups of this study population, showing excellent accept-
ability (Sampogna et al, 2003). It consists of a line-drawing
silhouette of the front and back of a body for patients to shade
in the affected areas and of three visual analog scales for recording
the erythema, induration, and scaliness of one’s own average
lesion. Based on the silhouette shading, a physician who had not
seen the patients and was blind to PASI scores assigned a numeric
value of 0 to 6 to the area of psoriatic involvement using the same
cut points of PASI (see above). SAPASI scores were calculated
as originally proposed (Feldman et al, 1996). The range and
interpretation of SAPASI scores are the same as those of PASI.
Health-related quality-of-life instruments: psoriasis-speciﬁc
Psoriasis Disability Index The Psoriasis Disability Index (PDI)
(Finlay and Kelly, 1987; Finlay and Coles, 1995) is a validated
self-administered questionnaire which consists of 15 questions
covering aspects of functional disability owing to psoriasis. To
answer the questions, patients had to refer to the immediately
preceding 4 wk. The 15 questions were grouped under four
headings: daily activities, work, personal relationship, and treat-
ment. Answers were recorded on a 4-point linear scale, indicating
grades from ‘‘not at all’’ to ‘‘very much.’’ The total score was
obtained by summing the scores given to each question.
Impact of psoriasis on quality of life The Impact of Psoriasis
Questionnaire (IPSO) (McKenna and Stern, 1997) assesses the
impact of psoriasis on patients’ physical, psychological, and social
functions. It is a self-administered questionnaire, with 16 questions
based on those used in the Medical Outcomes Study Short-Form
General Health Survey (Stewart et al, 1989). We considered the
sum of the scores for each question (from 0 to 4) as the total score.
Health-related quality-of life instruments: dermatology-speciﬁc
Skindex-29 Skindex-29 is a reliable and valid instrument that has
been specifically designed for measuring health-related quality of
life in dermatologic patients (Chren et al, 1997). It is constituted by
three scales assessing areas considered essential in any instru-
ment purported to assess quality of life: burden of symptoms,
social functioning, and emotional state. The Italian version of this
self-administered questionnaire has been recently validated (Abeni
et al, 2001, 2002). Patients answered the 29 questions referring to
the previous 4-wk period, on a 5-point scale, from ‘‘never’’ to ‘‘all
the time.’’ The total score of each scale was given by the sum of
the scores given to each question.
Dermatology Life Quality Index The Dermatology Life Quality Index
(DLQI) is a 10-item self-administered questionnaire (Finlay and
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Khan, 1994) designed to provide a simple method of measuring the
disability experienced by patients with skin diseases. The patients
answered the questions considering the previous week on a 4-
point scale, indicating ‘‘not at all,’’ ‘‘a little,’’ ‘‘a lot,’’ and ‘‘very
much,’’ respectively. The total DLQI score represents the sum of
the scores for each question.
Speciﬁc and generic measures of psychological distress
Psoriasis Life Stress Inventory The 15-item version of Psoriasis
Life Stress Inventory (PLSI) (Gupta and Gupta, 1995) was
developed to measure stress associated with potential psoriasis-
related psychosocial problems. Subsequent research (Fortune
et al, 1997b) has shown that the PLSI addresses specifically: (1)
stress resulting from anticipatory/avoidance coping behavior that
is effected to limit the sociocognitive intrusiveness of psoriasis and
(2) stress resulting from patients’ actual experiences or beliefs of
being evaluated by others solely on the basis of their skin. For each
item, the patient was asked to rate the level of stress experienced
over the previous month on a 4-point scale, from ‘‘not at all’’ to ‘‘a
great deal.’’ The PLSI score was calculated by summing the scores
for each question.
General Health Questionnaire The 12-item General Health Ques-
tionnaire (GHQ) is a self-administered questionnaire designed
to measure psychological distress and to detect current non-
psychotic psychiatric disorders (Goldberg, 1972). Questions refer
to the most recent weeks. The 12-item Italian version was used
(Bellantuono et al, 1987). The reliability and validity of this
instrument has been consistently demonstrated, recently also
in dermatologic patients (Picardi et al, 2001). Scores are given on a
4-point linear scale and higher scores on the GHQ-12 indicate
a higher level of psychological distress.
Assessment procedures During the first hours of hospitalization,
before any medication was administered, the dermatologists
assessed the clinical severity using the PASI. They also collected
information on sociodemographic variables, clinical history, and
other factors of clinical interest (e.g., clinical type and location of
the disease, personal and family history of psoriasis and other
diseases, symptoms). At the end of the visit, the physician rated
the global severity of the disease on a 5-point scale used in
previous studies (Chren et al, 1997; Abeni et al, 2002). The two
higher classes of severity were grouped together because of
scarce numbers.
After the visit, the self-administered questionnaires, each
stapled separately, were given to the patients in the following
order: sociodemographic information and history, Skindex-29,
GHQ-12, PDI, DLQI, IPSO, PLSI, and SAPASI. Patients were
instructed to complete the questionnaires as soon as possible, but
at the same time without feeling overburdened; they also had to
record time and date of completion on each questionnaire. Before
hospital discharge, the patients returned all the self-administered
questionnaires to their physicians.
Statistical analysis A single linkage hierarchical cluster analysis
(Sokal and Michener, 1958) was performed on the different
instruments to see whether groups with similar characteristics
could be identified. We used Pearson correlation coefficient (r) as a
measure of similarity between variables. The sequence of mergers
of clusters was visually represented by a tree diagram. As a
validation of the results obtained, we performed a replication
procedure: the same analysis was conducted on different random
samples, each including 50% of the total study population.
We then analyzed more in detail the correlations between the
clinical severity measured by PASI and SAPASI and the quality of
life as assessed by all the other instruments, considering them in
different levels of many variables. The considered variables were
sex, age, marital status, education, age at onset, duration and
severity of psoriasis, clinical type, localization, and symptoms. All
analyses were performed using the logarithm of PASI and SAPASI
scores, because of skewness in the distributions of the values of
both measures, to comply with a basic assumption of the analysis
of correlation (i.e., normal frequency distribution of the measures to
correlate). The other scores were not transformed, because we
observed that logarithmic or square root transformation, although
slightly improving the symmetry of distributions, did not change the
results.
To verify whether correlation coefficients could be influenced by
the time interval between the completion of the questionnaires we
performed a stratified analysis after classifying the questionnaires
into four categories based on time of completion: o 24, 24 to 35,
36 to 47, andX 48 h from admission. All statistical analyses were
performed under SPSS, version 9.0 for Windows (Norusis, 1999).
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